Abstract
Novel potent derivatives of phthalazine are described as ATP-competitive inhibitors of vascular endothelial growth factor receptors I and II (VEGFR-1/2). A number of compounds display VEGFR-2 inhibitory activity reaching that of Vatalanib 3 (IC50 < 100 nm) in an HTRF enzymatic assay. Several derivatives also show good potential for the development as VEGFR-2 specific inhibitors showing 15-20-fold selectivity over VEGFR-1.
MeSH terms
-
Adenosine Triphosphate / chemistry
-
Binding, Competitive
-
Drug Design
-
Humans
-
Phthalazines / chemistry*
-
Phthalazines / pharmacology*
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacology*
-
Pyridines / pharmacology
-
Structure-Activity Relationship
-
Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*
Substances
-
Phthalazines
-
Protein Kinase Inhibitors
-
Pyridines
-
vatalanib
-
Adenosine Triphosphate
-
Vascular Endothelial Growth Factor Receptor-1
-
Vascular Endothelial Growth Factor Receptor-2